In addition, in this pedigree, we also observed a preferential development of CRC with TP53 mutations in germline CHEK2 mutant carriers, where CHEK2 second-hit inactivation may precede TP53 mutation. This evidence concerns the gene CHEK2 and colorectal carcinoma.